In 2015 Mylan had about $1.5B in sales of EpiPens and those sales accounted for 40% of Mylan's profit.[26] Mylan had maintained about a 90% market share since it had acquired the product, and had continually raised the price of EpiPens starting in 2009: in 2009, the wholesale price of two EpiPens was about $100; by July 2013, the price was about $265; in May 2015, it was around $461; and in May 2016, the price rose again to around $609,[25] around a 500% jump from the price in 2009.[75] The cost of the drug and device to Mylan as of 2016 was about $35.[28] In the summer of 2016, as parents prepared to send their children back to school and went to pharmacies to get new EpiPens, people began to express outrage at the cost of the EpiPen and Mylan was widely and harshly criticized.[76][77] In September 2016, the New York State Attorney General began an investigation into Mylan's EpiPen4Schools program in New York to determine if the program's contracts violated antitrust law[78] and the West Virginia State Attorney General opened an investigation into whether Mylan had given the state the correct discount under the Medicaid Drug Rebate Program and subpoenaed the company when it refused to provide the documentation the state requested.[79] In October 2016, Mylan announced a $465M settlement with the US Department of Justice over rebates paid by Mylan to states under the Medicaid Drug Rebate Program.[80]
As of 2015, the following epinephrine autoinjectors were available in various parts of Europe: Adrenalina WZF, Adrenaline (epinephrine) 1 in 1000 solution for injection BP auto-injector, Altellus, Anapen, Emerade, EpiPen, Fastjekt, FastPen, and Jext.[83] As of 2014, three branded products were available in the US: Adrenaclick, Auvi-Q, and EpiPen,[5] but as of October 2015 Auvi-Q was no longer available.[72] They state it will be available again in February 2017.[84] As of 2005, epinephrine autoinjectors were not available in most of the developing world.[5]
https://en.wikipedia.org/wiki/Epinephrine_autoinjector